Home › Companies › GOSS

Gossamer Bio

Market cap $67.5M 6.1M shares (10-Q, Nov 7, 2026) × $11.04 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. RT234 Inhaled Vardenafil trial start2027RT234 Inhaled Vardenafil trial start, 2027, routine
  2. 2030 Notes corporate updateMar 2, 20272030 Notes corporate update, Mar 2, 2027, routine
  3. seralutinib PAH FDA approval3Q 2027seralutinib PAH FDA approval, 3Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Capital (as filed)

Cash
$51.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$29.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$51.2M cash, runway into the first quarter of 2027 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Gossamer Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Gossamer Bio (GOSS): Scientific Deep Dive for Seralutinib The biological mechanism is sound but clinical execution risk is high, relying on a post-hoc subgroup analysis from a failed Phase 2; wait for PROSERA results before taking a position.
  2. Avoid UPDATE: Gossamer Bio (GOSS) - The Enrichment Trap Springs Shut Phase 3 PROSERA missed its primary endpoint, confirming the Phase 2 subgroup signal was a statistical artifact; Chiesi terminated the partnership, and the convertible debt overhang makes the equity functionally worthless.
  3. Avoid UPDATE: Gossamer (GOSS) - The Anatomy of a Biotech Death Spiral Going-concern qualification, closed capital markets via Baby Shelf Rule, and Nasdaq delisting risk confirm Gossamer is now a distressed financial vehicle with no viable drug pipeline.
  4. Avoid UPDATE: Gossamer Bio (GOSS) - The Zombie Files Its Q1, and a Class Action Arrives Cash runway is shorter than the debt maturity, the Hail Mary NDA plan does not change the $99M-vs-$198M arithmetic, and a new class action adds liability ahead of equity holders.
  5. Avoid UPDATE: Gossamer Bio (GOSS) - The Debt Wall Comes Down, and So Does the Equity The debt-for-equity exchange triples the float in noteholder hands, forces a mandatory $100-150M equity raise, and leaves common shareholders diluted into a sliver behind $72M of secured first-lien debt.
  6. Avoid UPDATE: Gossamer Bio (GOSS) - The Zombie Gets a Filing Path FDA distinguished filing from review issues giving a non-frivolous NDA pathway, and debt was cut by $115.9M, but cash is down to ~$57M against a $40M monthly covenant, approval remains the less likely outcome, and existing common faces further dilution from a mandatory equity raise.
  7. Avoid UPDATE: Gossamer Bio (GOSS) - The Debt Wall Didn't Move to 2030. It Moved to March. The 2030 notes carry a springing maturity to March 2, 2027 controlled by a single holdout bondholder, the debt wall was relocated not removed, and common sits behind a covenant-mandated dilution funnel with a shorter fuse than previously understood.
  8. Watch UPDATE: Gossamer Bio (GOSS) - Somebody Just Underwrote the Hail Mary A $250M structured placement with $150M committed capital defuses the March 2027 detonator and extends runway into 2028, removing the bankruptcy/wipeout branch, but the drug's efficacy versus Winrevair is unchanged and existing common faces 3-4x dilution.
  9. Watch UPDATE: Gossamer Bio (GOSS) - The Ratio Lands at 1-for-80 The 1-for-80 reverse split with authorized shares cut from 4B to 50M makes the dilution ceiling visible and the vehicle legible, but the drug's efficacy versus Winrevair is unchanged and the March 2027 stub trigger remains unresolved.
  10. Watch UPDATE: Gossamer Bio (GOSS) - The NDA Is In. The Clock Is Running. NDA submission confirmed on schedule, putting the FDA filing-acceptance decision inside the December 31 deadline for the $125M tranche, but the drug's efficacy is unchanged and the $18.9M stub and March 2027 springing maturity remain unresolved.
  11. Watch UPDATE: Gossamer Bio (GOSS) - The Mailroom Bet Becomes a Survival Bet Only $11.2M cushion above the $40M liquidity covenant with ~$84M of debt potentially due in H1 2027 means FDA filing acceptance is now a survival event, not just an upside catalyst; approval remains the less likely outcome.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (54)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 15, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

19 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)